drugset / Trial / NCT00263744
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
RandomizedParallel-groupDouble-blindPrevention
Summary
The primary objective of this study is to describe the safety of 40 mg MEDI-517, with a control of aluminum hydroxide, when given to healthy adult women who have evidence of HPV-16 and/or HPV-18 DNA detected in cervical brushings.
Timeline
- Start
- 1999-11
- Primary completion
- 2001-04
- Completion
- 2001-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI-517 | Vaccine | 40 mg | — |
Indications
No indication recorded.